Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Early Hum Dev. 2015 May 15;91(7):387–392. doi: 10.1016/j.earlhumdev.2015.04.008

Table 2. Octreotide indications.

Courses, n (%)* N = 490
Chylothorax 245 (50)
Pleural effusion 158 (32)
Hypoglycemia 110 (22)
Gastrointestinal hemorrhage 48 (10)
Bloody stools 25 (5)
Pericardial effusion – acute 13 (3)
Lymphangiectasia 3 (1)
Congenital lymphedema 1 (0.2)
*

Multiple diagnoses per course were allowed; thus, sum of % >100.